Related Experiment Videos
Increased plasma VIP concentration in patients with prolactinoma
A Makowska1, W Zgliczyński, J Słowińska-Srzednicka
1Department of Endocrinology, Medical Centre for Postgraduate Education, Warsaw.
Endokrynologia Polska
|January 1, 1992
Summary
Vasoactive intestinal polypeptide (VIP) levels are elevated in patients with prolactin-secreting adenomas. Bromocriptine treatment did not alter VIP concentrations in these patients.
Area of Science:
- Endocrinology
- Neuroendocrinology
- Oncology
Background:
- Vasoactive intestinal polypeptide (VIP) is recognized as a prolactin-releasing factor (PRF).
- Prolactinomas are pituitary tumors that secrete prolactin, potentially influenced by PRFs.
Purpose of the Study:
- To compare peripheral blood VIP concentrations in prolactinoma patients versus healthy individuals.
- To investigate the impact of bromocriptine on plasma VIP levels in prolactinoma patients.
Main Methods:
- Radioimmunoassay was used to measure serum prolactin and plasma VIP levels.
- Blood samples were collected from 9 prolactinoma patients and 7 healthy controls at multiple time points.
- VIP levels were assessed before and after bromocriptine administration in patients.
Main Results:
- Plasma VIP concentration was significantly higher in patients with prolactinoma compared to healthy subjects.
- Bromocriptine administration led to a decrease in mean prolactin concentration within 24 hours.
- No significant change in plasma VIP levels was observed after bromocriptine treatment.
Conclusions:
- Patients with prolactin-secreting adenomas exhibit increased plasma VIP concentrations.
- VIP levels in prolactinoma patients are not affected by acute bromocriptine administration.